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Monday, March 7, 2011 219a(300B) and1-(2,2-Bis-phosphono-ethyl)-3-butyl-pyridinium (476A) are 4.68mM
and 6.48 mM respectively. Isothermal Calorimetric studies with these inhibitors
revealed that the binding is entropically driven. X-ray crystallographic structures
of the LmFPPS in complex with 300B, Isopentenyl Pyrophosphate (IPP), and 3
divalent cations and the other in complex with 476A, IPP and 3 divalent cations
were determined.Comparison of these structureswith thoseof the humanenzyme
complexedwith zolendronate reveals significant differences in residues at thebot-
tom of the pocket, such as Glu97 and Leu129, that could be used to tailor speci-
ficity of the bisphosphonates to the parasitic enzyme.
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Computational Enzyme Design: Refining Artificial Enzymes and Explor-
ing Paths of Directed Evolution
Maria P. Frushicheva, Arieh Warshel.
A fundamental challenge in biotechnology and in biochemistry is the ability to
design effective enzymes. In fact, it would be one of the most convincing in-
dications of a full understanding of the origin of enzyme catalysis. Despite
a gradual progress on this front, most of the advances have been made by plac-
ing the reacting fragments in the proper places rather than by optimizing the
environment preorganization, which is the key factor in enzyme catalysis
(Chem. Rev. 2006, 106, 3210-3235). Improving the preorganization and as-
sessing the effectiveness of different design options requires the ability to cal-
culate the actual catalytic effect. Our studies are based on using the empirical
valence bond (EVB) as the main screening tool (for e.g., Biochemistry 2009,
48, 3046-3056). At present this approach appears to provide the most reliable
way for quantifying catalytic effects. Previously, we explored the challenges of
the rational enzyme design in artificial Kemp eliminases with glutamate as
a base (Frushicheva et al., PNAS, Sept 09 2010). It has been shown that due
to the small change in substrate charges upon reaching the transition state
makes it hard to exploit the active site polarity. This appears to be the case
even with the ability to quantify the effect of different mutations. Thus we
study the catalytic effect of the Kemp elimination reaction with different cat-
alytic bases, such as histidine and lysine. This allowed us to exploit change in
basicity as well the larger dipole of the transition charge distribution. We also
investigate the effect of mutations that convert the highly catalytic phospho-
triestrase to a lactonase. Overall we are able to illustrate the effectiveness of
the EVB as a powerful approach for a quantitative screening in rational en-
zyme design.
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Mechanical Tuning of a Catalytic Cystein PKA in Thioredoxin
Pallav Kosuri, Bo Chen, Arne Holmgren, Julio M. Ferna´ndez.
Protein function is often modulated by the protonation state of functional
groups. Thioredoxin is a universally conserved disulfide reductase with wide
substrate specificity, and its catalytic activity is dependent on the deprotonation
of Cys32. This cysteine exhibits a pKa that is markedly lower than free cysteine,
ensuring catalytic activity at physiological pH. Various electrostatic effects
within the active site have been suggested to cause this pKa depression. How-
ever, a consensus on the actual pKa value is still lacking, as reported values
have differed depending on the method used. We show here that the pKa of
Cys32 in human thioredoxin can be modulated by its substrate. We used an
atomic force microscope to detect single disulfide cleavage events in immuno-
globulin substrate proteins. Integrating the data from many such events for
a range of pH conditions enabled precise measurement of the rate of nucleo-
philic attack by thioredoxin, which is linearly dependent on nucleophile con-
centration. Fits to the Henderson-Hasselbalch equation allowed for sensitive
titration of the Cys32 pKa. Interestingly, when altering the mechanical strain
on the substrate we observed a concomitant change in the enzyme pKa. We
could in this manner continuously tune the Cys32 pKa between 6.5 and 7.5.
These results suggest that the conformation of the substrate influences the en-
zyme pKa. Electrostatic interactions in the enzyme-substrate binding interface
could be responsible for this modulation. The substrate dependence of the
Cys32 pKa could explain why previous reports have failed to reach a consensus
on its value. Our findings may indicate a general phenomenon, which brings
into question the relevance of measuring enzyme pKa’s in the absence of phys-
iological substrates.
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Heptosyltransferase I Lipid a Structure Activity Relationships (SAR)
Daniel J. Czyzyk, Erika A. Taylor.
The increasing incidence of antibiotic resistant bacterial infections has neces-
sitated the search for novel targets and mechanisms for therapeutic interven-
tion. Formation of a biofilm enables survival of bacteria in hostile
environments, including in the presence of antimicrobials, thereby prompting
research toward the disruption of bacterial biofilms. Lipopolysaccharide
(LPS), a major constituent of the outer membrane of gram-negative bacteria,plays a key role in the formation and stability of biofilms. Therefore, disrupt-
ing the biosynthesis of the LPS is an attractive mechanism for development
of anti-biofilm agents. One such LPS biosynthetic enzyme is heptosyltrans-
ferase I (Hep I), which is responsible for the transfer of the first L-glyc-
ero-D-manno-heptose to a 3-deoxy-a-D-manno-oct-2-ulopyranosonic acid
(KDO) of the growing Lipid A portion of LPS. Previous attempts to co-crys-
tallize Hep I with both substrates have been unsuccessful, hindering the abil-
ity to effectively visualize the binding interactions important for specificity.
Substrate analogues for E. coli Hep I Lipid A are being used to identify
which portions are necessary and sufficient for binding. Determination of
the SAR of Hep I for these analogues may lead to the discovery of a Lipid
A analogue that is able to be co-crystallized with Hep I. Developing an un-
derstanding of E.coli Hep I binding interactions with lipid A will enhance ef-
forts to develop a Hep I inhibitor and possibly the discovery of a new anti-
biofilm agent.
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Soheila Adl.
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Dihdyropteridine reductase (DHPR) catalyzes reduction of the unstable quino-
noid dihydropteridine to the active tetrahydropteridine form through the oxida-
tion of NADH. DHPR deficiency or any blockage in biosynthesis of
tetrahydropteridine results in development of phenylketonuria (PKU), a pro-
gressive neurological illness which does not respond to dietary treatment. It
has been speculated that DHPR or metabolites associated with it may have anti-
oxidative properties. In another study, DHPR has been shown to have NADH-
ferric reductase activity. This activity is postulated to have an important role in
dietary iron uptake. There is an emerging role, though mechanistically unclear
at this point, for BH4 in maintaining nitric oxide synthase (NOS) activity. NOS
produces the signaling agent nitric oxide (NO) from L-arginine. In the light of
these emerging roles there is a growing need to completely understand how
DHPR works.
The mechanism of catalysis in DHPR is not fully understood. Previous studies
have suggested the involvement of the thiol group of a cysteine residue in
DHPR. DFT computational modeling of Raman spectra of the unlabeled and
isolabeled inhibitor of DHPR provides valuable information for assigning
Raman marker bands which are involved in enzyme- inhibitor interactions. Us-
ing Raman spectroscopic techniques, the effect of the inhibitors/substrate and/
or cofactor on the protonation state of the thiol group is investigated. Raman
spectroscopy is particularly effective because of a unique peak at ca. 2500
cm-1 due to the S-H stretch and another one at ca. 900 cm-1 due to the C-S
bond. Peak shifts and modulation in intensities are monitored and analyzed
in terms of its mechanistic implications.1199-Pos Board B109
Structural and Functional Studies of a New Isoform of Indoleamine 2, 3-
dioxygenase
Laura B. Granell-Ortiz, Dr. Syun-Ru Yeh.
Indoleamine 2, 3-dioxygenase-1 (IDO1) is a heme-containing enzyme that cat-
alyzes the first and rate-limiting step of the kynurenine (KYN) pathway, the
major catabolic route of L-tryptophan (L-Trp). Expression of IDO1 is induced
by immunological stimuli (e.g. interferon gamma), causing T-cell inhibition.
Therefore, IDO1 has been implicated in various physiological and patho-phys-
iological processes, including viral infections and cancer. In cancer cells, IDO1
is expressed to help tumors evade immune surveillance, resulting in uncon-
trolled tumor growth and cancer progression. The IDO1 inhibitor, 1-methyl-
tryptophan (1MT) has been known to inhibit mouse IDO1 and, together with
chemotherapeutic agents, to reduce tumor size. However, additional tests re-
vealed that the L-isomer of 1-MT has more potent inhibitory efficiency in vitro
with purified IDO1, while the D-isomer is more potent in vivo. The discrepancy
of these results was partially answered by the recent discovery of a new isoform
of IDO1, named IDO2, which have been shown to be preferentially inhibited by
D-1MT in vivo. Although, D-1MT is in phase I clinical trials, no structural or
molecular studies of purified human IDO2 has been reported so far. Hence,
there exists a critical need for the understanding of the structural and functional
properties of IDO2, in order to clarify the physiological functions of IDO2 to
provide guidelines for the development of new and potent drugs for cancer ther-
apy. To obtain a better insight into the structure-function of IDO2 we have
cloned, expressed and purified recombinant human IDO2. Our spectroscopic
and kinetic data provide a glimpse of the structural and functional properties
of IDO2 for the first time, and suggest that the action mechanism of IDO2 is
distinctive from IDO1.
